This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.
The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma
October 5th 2022During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.